Hypoparathyroidism in children is a heterogeneous group with diverse genetic etiologies. To aid clinicians in the investigation and management of children with hypoparathyroidism, we describe the phenotype of a 6-year-old child with hypoparathyroidism and short stature diagnosed with Kenny-Caffey syndrome (KCS) Type 2 and the subsequent response to growth hormone (GH) treatment.
The proband presented in the neonatal period with hypocalcemic seizures secondary to hypoparathyroidism. Her phenotype included small hands and feet, hypoplastic and dystrophic nails, hypoplastic mid-face and macrocrania. Postnatal growth was delayed but neurodevelopment was normal. A skeletal survey at 2 years of age was suggestive of KCS Type 2 and genetic testing revealed a novel de novo heterozygous mutation c.1622C > A (p.Ser541Tyr) in FAM111A. At 3 years and 2 months, her height was 80cms (SDS −3.86). She had normal overnight GH levels. GH therapy was commenced at a dose of 4.9 mg/m2/week for her short stature and low height velocity of 5cms/year. At the end of the first and second years of GH treatment, height velocity was 6.5cms/year and 7.2cms/year, respectively with maximal dose of 7.24 mg/m2/week.
This case highlights the phenotype and the limited response to GH in a child with genetically proven KCS type 2. Long-term registries monitoring growth outcomes following GH therapy in patients with rare genetic conditions may help guide clinical decisions regarding the use and doses of GH in these conditions.
Kim JH, Shin YL, Yang S, et al. Diverse genetic aetiologies and clinical outcomes of paediatric hypoparathyroidism. Clin endocrinol (Oxf). 2015;83(6):790–6. CrossRef
Honda Y, Takahashi K, Takahashi S, et al. Growth hormone secretion during nocturnal sleep in normal subjects. The Journal of clinical endocrinology and metabolism (1969);29: 20–29
Hughes IP, Harris M, Cotterill A, et al. Comparison of weight- vs body surface area-based growth hormone dosing for children: implications for response. Clin endocrinol (Oxf). 2014;80:384–94. CrossRef
Department of Health:Guidelines for the Pharmaceutical Benefit Scheme Growth HormoneProgramme. Available from http://www.health.gov.au/hgh. Accessed 11 Nov 2014.
Tennessen JA, Bigham AW, O’Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (New York, NY). 2012;337:64–9. CrossRef
Isojima T, Doi K, Mitsui J, et al. A recurrent de novo FAM111A mutation causes Kenny-Caffey syndrome type 2. J bone miner res off j am soc bone miner res. 2014;29:992–8. CrossRef
Bauters M, Guo M, Dauber A, Walvoord E. Kenny-Caffey syndrome: an expanded phenotype and response to growth hormone therapy. Chicago: ICE/ENDO 2014; 2014.
Hughes IP, Choong C, Rath S, et al. Early cessation and non-response are important and possibly related problems in growth hormone therapy: an OZGROW analysis. Growth hormon IGF res off j growth hormon res soc int IGF res soc. 2016;29:63–70. CrossRef
- Short stature and hypoparathyroidism in a child with Kenny-Caffey syndrome type 2 due to a novel mutation in FAM111A gene
Mary B. Abraham
Susan M. O’Connell
Ee Mun Lim
Michael A. Levine
Catherine S. Choong
- BioMed Central
Neu im Fachgebiet Pädiatrie
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II